Janux Therapeutics Past Earnings Performance
Past criteria checks 0/6
Janux Therapeutics's earnings have been declining at an average annual rate of -50.4%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 63.3% per year.
Key information
-50.4%
Earnings growth rate
55.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 63.3% |
| Return on equity | -16.9% |
| Net Margin | -721.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Revenue & Expenses BreakdownBeta
How Janux Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -58 | 26 | 47 |
| 30 Sep 23 | 8 | -63 | 25 | 0 |
| 30 Jun 23 | 8 | -68 | 25 | 0 |
| 31 Mar 23 | 9 | -67 | 24 | 0 |
| 31 Dec 22 | 9 | -63 | 22 | 46 |
| 30 Sep 22 | 7 | -60 | 21 | 0 |
| 30 Jun 22 | 7 | -54 | 18 | 0 |
| 31 Mar 22 | 5 | -44 | 15 | 0 |
| 31 Dec 21 | 4 | -33 | 10 | 0 |
| 30 Sep 21 | 2 | -21 | 7 | 0 |
| 30 Jun 21 | 1 | -11 | 4 | 0 |
| 31 Mar 21 | 0 | -8 | 2 | 0 |
| 31 Dec 20 | 0 | -7 | 2 | 0 |
Quality Earnings: JANX is currently unprofitable.
Growing Profit Margin: JANX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JANX is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.
Accelerating Growth: Unable to compare JANX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JANX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: JANX has a negative Return on Equity (-16.93%), as it is currently unprofitable.